Vertex Pharmaceuticals showed strong Q2 2023 earnings, with a 14% revenue increase driven by international sales of Trikafta/Kaftrio and U.S. growth. Management outlined growth initiatives in various ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results